top of page
Stellar_Logo-temp-download.png
Contact Exelixis
Legacy materials for HLM_edited.png
Legacy materials for HLM.png
STELLAR-316 logo

ACTIVELY RECRUITING

Randomized Phase 3 Study of Zanzalintinib ± Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) vs Placebo in Patients with Stage II/III Colorectal Cancer with Molecular Residual Disease Following Definitive Therapy

ZANZALINTINIB AND THE COMBINATION OF ZANZALINTINIB AND MK-3475A IS NOT APPROVED FOR THE USE UNDER INVESTIGATION IN THIS TRIAL. SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED.

Study Overview

Approximately 600 eligible patients with stage II/III CRC who have MRD after completing definitive therapies will be randomized in a 1:1:1 ratio to receive zanzalintinib + MK-3475A, zanzalintinib monotherapy, or placebo to evaluate the effect of zanzalintinib + MK-3475A and zanzalintinib monotherapy on DFS vs placebo.

Study Diagram

Stratification Factors

  • Site: Colon vs rectal

  • Mean tumor molecules (MTM): <1 vs ≥1 MTM/mL

  • Timing of ctDNA positivity: ≤8 weeks vs >8 weeks after definitive therapy

Key Elgibility Criteria

  • ​Histologically confirmed stage II/III adenocarcinoma of the colon or rectum

  • Documented MSS, MSI-low, or pMMR status

  • Completion of definitive therapy (R0 resection and ≥3 months of oxaliplatin‑containing neoadjuvant and/or adjuvant chemotherapy)

  • ctDNA-positive based on the Natera Signatera tissue-informed MRD assay

  • No evidence of radiographic disease

  • No prior treatment with ICIs or VEGFR inhibitors

Key Endpoints

Primary Endpoint

  • DFS by investigator (combination & monotherapy vs placebo)

Secondary Endpoints

  • Proportion of patients with ctDNA clearance
    (combination & monotherapy vs placebo)

  • OS
    (combination & monotherapy vs placebo)

  • DFS by investigator
    (combination vs monotherapy)

  • Safety and tolerability

Exploratory Endpoints

  • TTR by investigator

  • ctDNA dynamics

  • HRQoL by EORTC QLQ-C30

CRC, colorectal cancer; ctDNA, circulating tumor DNA; DFS, disease-free survival; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30; HRQoL, health-related quality of life; ICI, immune checkpoint inhibitor; MRD, molecular residual disease; MSI-low, microsatellite instability–low; MSS, microsatellite stable; MTM, mean tumor molecules; OS, overall survival; pMMR, proficient mismatch repair; q3w, once every 3 weeks; qd, once daily; SC, subcutaneous; TTR, time to recurrence; VEGFR, vascular endothelial growth factor receptor

Participating Sites

STELLAR-316 will be conducted in North America. Call 1-888-393-5494 (toll-free) or 1-303-389-1847 for specific location and site information and to confirm whether sites near you are still enrolling new patients.

​

Currently open or planned clinical site cities:

Trial sites may stop enrolling patients at any time. Please check back if you do not see a trial site located near you.

decorative
Legacy materials for HLM.png
decorative
decorative
STELLAR-316 logo

ACTIVE, NOT RECRUITING

Randomized Phase 3 Study of Zanzalintinib ± Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) vs Placebo in Patients with Stage II/III Colorectal Cancer with Molecular Residual Disease Following Definitive Therapy

ZANZALINTINIB AND THE COMBINATION OF ZANZALINTINIB AND MK-3475A IS NOT APPROVED FOR THE USE UNDER INVESTIGATION IN THIS TRIAL. SAFETY AND EFFICACY HAVE NOT BEEN ESTABLISHED.

bottom of page